69 related articles for article (PubMed ID: 11023475)
1. The amino acid sequence of the PKR-eIF2alpha phosphorylation homology domain of hepatitis C virus envelope 2 protein and response to interferon-alpha.
Cochrane A; Orr A; Shaw ML; Mills PR; McCruden EA
J Infect Dis; 2000 Nov; 182(5):1515-8. PubMed ID: 11023475
[TBL] [Abstract][Full Text] [Related]
2. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon.
Polyak SJ; Nousbaum JB; Larson AM; Cotler S; Carithers RL; Gretch DR
J Infect Dis; 2000 Aug; 182(2):397-404. PubMed ID: 10915068
[TBL] [Abstract][Full Text] [Related]
3. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
[TBL] [Abstract][Full Text] [Related]
5. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy.
Chayama K; Suzuki F; Tsubota A; Kobayashi M; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Takahashi N; Kinoshita M; Kumada H
Hepatology; 2000 Nov; 32(5):1138-44. PubMed ID: 11050067
[TBL] [Abstract][Full Text] [Related]
6. Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.
Gaudy C; Lambelé M; Moreau A; Veillon P; Lunel F; Goudeau A
J Clin Microbiol; 2005 Feb; 43(2):750-4. PubMed ID: 15695675
[TBL] [Abstract][Full Text] [Related]
7. Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load.
Ukai K; Ishigami M; Yoshioka K; Kawabe N; Katano Y; Hayashi K; Honda T; Yano M; Goto H
World J Gastroenterol; 2006 Jun; 12(23):3722-8. PubMed ID: 16773689
[TBL] [Abstract][Full Text] [Related]
8. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
Murphy MD; Rosen HR; Marousek GI; Chou S
Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
[TBL] [Abstract][Full Text] [Related]
9. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.
Sarrazin C; Bruckner M; Herrmann E; Rüster B; Bruch K; Roth WK; Zeuzem S
Virology; 2001 Oct; 289(1):150-63. PubMed ID: 11601926
[TBL] [Abstract][Full Text] [Related]
10. Lack of clinical evidence for involvement of hepatitis C virus interferon-alpha sensitivity-determining region variability in RNA-dependent protein kinase-mediated cellular antiviral responses.
Mihm S; Monazahian M; Grethe S; Meier V; Thomssen R; Ramadori G
J Med Virol; 2000 May; 61(1):29-36. PubMed ID: 10745229
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.
Berg T; Mas Marques A; Höhne M; Wiedenmann B; Hopf U; Schreier E
Hepatology; 2000 Dec; 32(6):1386-95. PubMed ID: 11093746
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients.
Afzal S; Idrees M; Akram M; Awan Z; Khubaib B; Aftab M; Fatima Z; Badar S; Hussain A
Virol J; 2010 Dec; 7():377. PubMed ID: 21194456
[TBL] [Abstract][Full Text] [Related]
13. [Structural analysis of the PKR-binding region of HCV 1b samples from patients with chronic hepatitis C and the correlation with IFN-sensitivity].
Gervain J; Czibula A; Simon J; Kalmár T
Orv Hetil; 2003 Jun; 144(24):1179-84. PubMed ID: 12866147
[TBL] [Abstract][Full Text] [Related]
14. [Association between NS5A gene sequence and response to interferon therapy in chronic hepatitis C patients in Shanghai].
Hu Y; Tang M; Jiang W; Wu Y; Yuan Z; Wen Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Jun; 16(2):114-8. PubMed ID: 12196819
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.
Hofmann WP; Zeuzem S; Sarrazin C
J Clin Virol; 2005 Feb; 32(2):86-91. PubMed ID: 15653410
[TBL] [Abstract][Full Text] [Related]
17. Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients.
Hofmann WP; Sarrazin C; Kronenberger B; Schönberger B; Bruch K; Zeuzem S
J Infect Dis; 2003 Mar; 187(6):982-7. PubMed ID: 12660945
[TBL] [Abstract][Full Text] [Related]
18. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response.
Sarrazin C; Kornetzky I; Rüster B; Lee JH; Kronenberger B; Bruch K; Roth WK; Zeuzem S
Hepatology; 2000 Jun; 31(6):1360-70. PubMed ID: 10827164
[TBL] [Abstract][Full Text] [Related]
19. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.
Xu J; Liu S; Xu Y; Tien P; Gao G
Virus Res; 2009 Apr; 141(1):55-62. PubMed ID: 19185598
[TBL] [Abstract][Full Text] [Related]
20. Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection.
Bain C; Parroche P; Lavergne JP; Duverger B; Vieux C; Dubois V; Komurian-Pradel F; Trépo C; Gebuhrer L; Paranhos-Baccala G; Penin F; Inchauspé G
J Virol; 2004 Oct; 78(19):10460-9. PubMed ID: 15367612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
